Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: The MIRAR Study

Annals of the Rheumatic Diseases

Volumn 71, Issue 11, 2012, Pages 1861-1864

  Gomez Reino, Juan J ^a   Maneiro, Jose Ramon ^a   Ruiz, Jorge ^b   Roselló, Rosa ^c   Sanmarti, Raimon ^d   Romero, Ana Belen ^e   Garcia A ^f   Povedano, J ^f   Cejas, P ^f   Navarro, F ^f   Ariza Ariza, J A ^f   Ricca, S ^f   Burson J S ^f   Mediano, W H ^f   Ubeda, M A ^f   Blanca, P S ^f   Raya, E ^f   Garrido, P M ^f   Rueda, A ^f   Romero, M ^f   Fernandez A ^f   Belmonte, A ^f   Garcia R ^f   Ruiz A ^f   Venegas, J J ^f   Salberii, J ^f   Menor, R ^f   Grandal, Y ^f   Paez Camin, M ^f   del Mar Ruiz, M ^f   Mendoza, D ^f   Riesco, M ^f   Fernandez C ^f   Delgado, C ^f   Pina, ^f   Fabregas, D ^f   Alonso, J C ^f   Garcia F J ^f   Lopez M A ^f   Silva, R Q ^f   Noriega, J L ^f   Arboleya, L ^f   Tinture T ^f   Poch, L E ^f   Areste, J F ^f   Vilamajo I R ^f   Mai, A J ^f   Font, T ^f   Alemany, M P ^f   Arana, A U ^f   Bustabad, S ^f   Ferraz, I ^f   Cantabrana, A ^f   Batista, D ^f   Hdez, J A ^f   Quevedo, J C ^f   Rua Figueroa I ^f   Calvo, J ^f   Arrecoechea, E ^f   Jimeno, T ^f   Moragues, C ^f   Moller I ^f   Batina, N M ^f   Torne D ^f   Segarra, V T ^f   Acosta, A ^f   Bonet, M ^f   Kanterewicz, E ^f   Rodriguez, J ^f   Figuls, R ^f   Padro M L ^f   Gomez A ^f   Garcia J V ^f   Sirvent, E ^f   Rodríguez Sanz, David ^f   Ros, S ^f   del Blanco, J ^f   Maymo J ^f   Lisbona, M ^f   Perez C ^f   Almirall, M ^f   Perez, N A ^f   Sanchez S ^f   Olive A ^f   Garcia, E ^f   Salvador, G ^f   Riera, E ^f   Marsal, ^f   Rotes M I ^f   Moreno, E ^f   Claveguera, T ^f   Valls, R ^f   Sala, M ^f   Valls, M ^f   Rosello L ^f   Palau, S O ^f   Paredes, S ^f   Pujol, J ^f   Morla R ^f   Garrofi R F ^f   Elias, M J ^f   Arasa, X ^f   Querol, A L ^f   Judez, E ^f   Garcia, G ^f   Virginia, P ^f   Vazquez J ^f   Munoz P ^f   Alvarez J S ^f   Aparicio, A M ^f   Sanz, A H ^f   Rey Rey, J ^f   Corteguera, M ^f   Martinez M M ^f   Pantoja, L ^f   Montilla, ^f   Ruiz, P ^f   Santos, J M ^f   Vega, J L ^f   Salazar, J M ^f   Chamizo, E ^f   Aznar, J J ^f   Garrido, N ^f   Escarcena, A C ^f   Conejo, A F ^f   Gonzalez R V ^f   Toron, J G ^f   Abad, M A ^f   Andres M T ^f   Freire, M ^f   Grana J ^f   Lopez M R ^f   Hernandez M A ^f   Rodriguez J B ^f   Garel, J J ^f   Fernandez M R ^f   Dominguez L F ^f   Dominguez A W ^f   Martinez, J C ^f   Ouvina R ^f   Hernandez I ^f   Barbazan C ^f   Cabezas, J A ^f   Estevez, J G ^f   Mateo, ^f   Joven, B ^f   Galindo, M ^f   Morillas, L ^f   Dapica, P F ^f   Hombrados, L G ^f   Herrera, P ^f   Garcia J ^f   Alcalde, M ^f   Naredo, E ^f   Paz, C ^f   Carreno L ^f   Salvat, M ^f   Monteagudo, I ^f   Crespo, ^f   Gonzalez, ^f   Lopez F J ^f   Rabaneda, E V ^f   Coledaro, E ^f   Atrio, S ^f   Cobo, T ^f   Steiner, M ^f   de Abreu, P ^f   Illera, O ^f   Sanchez R M ^f   Espartero, M C ^f   Garcia V V ^f   Valle, M M ^f   Jaefer, J U ^f   Zarco, P ^f   Prada, ^f   Mulero, ^f   Gonzalez M L ^f   Aragon A ^f   Escalera, C R ^f   Villalba, F G ^f   Ramos, M M ^f   Morales, J M ^f   Tornero, C ^f   Cuenca, E S ^f   Marras, C ^f   Lozano, N ^f   Aznar, E ^f   Sofia R ^f   Cortina, E L ^f   Fito, C ^f   del Val, N ^f   Ibanez R ^f   Gutierrez, R ^f   Vesga, J C ^f   Ruiz, A A ^f   Albizuri, J M ^f   Garcia M ^f   Galinder, E ^f   Ucar, E ^f   Gorordo, M ^f   Pacho, A ^f   Torre, I ^f   Garcia F ^f   Fernandez, O ^f   Torre, F ^f   Diez, A R ^f   Belzunegui, J ^f   Vela, P ^f   Jovani ^f   Belmonte, M ^f   Gonzalez J A ^f   Blasco, F N ^f   Beltran, J T ^f   Noguera, J R ^f   Minguez, M ^f   Perez F ^f   Alcaniz ^f   Perez A G ^f   Castellano, J A ^f   Gonzalez Cruz I ^f   more..

^a Instituto de Salud Carlos III   (Spain)

^b MIXESTAT SL   (Spain)

^c HOSPITAL SAN JORGE   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e Roche Laboratories   (Spain)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

28 JOINT DISEASE ACTIVITY SCORE; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; DISEASE DURATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84867404092     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201324     Document Type: Article

References (9)

1. Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
2. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387-93.
3. Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012 (in press).
4. Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 2011;31:39-51.
5. Wolfe F, Lassere M, van der Heijde D, et al. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol 1999;26:484-9. (Pubitemid 29066762)
6. D'Agostino RBJ. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
7. Verbeke G, Molenberghs G. Linear mixed models in practice: a SAS-oriented approach. New York: Springer-Verlag, 1997.
8. Krishnan E, Fries JF. Measuring effectiveness of drugs in observational databanks: promises and perils. Arthritis Res Ther 2004;6:41-4. (Pubitemid 38444460)
9. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999;150:327-33. (Pubitemid 29383480)